Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of naldemedine for opioid-induced constipation in non-malignant chronic pain patients receiving oxycodone (S-8117)
jRCT2080222556Phase 3
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of naldemedine in opioid-induced constipation (OIC) and Chronic non-cancer pain (CNCP), sponsored by Shionogi & Co., Ltd.
02
Drugs
naldemedine
03
Conditions
opioid-induced constipation (OIC)Chronic non-cancer pain (CNCP)
Beyond the preview
Go deeper on jRCT2080222556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222556.